Treatment of asthenic syndrome in chronic brain ischemia: TRIUMPH observational program
Observational study · 2014
- What was studied
- 2,029 participants; 1,170 analyzed; 859 excluded for protocol completion/documentation problems
- Main finding
- Fatigue scores declined in an observational program, with large exclusions from analysis and no untreated group.
General-fatigue reduction at three months · 59.1%, 55.9%, 60.5% and 55.7% · Four age-by-duration subgroups; within-person reductions, not a placebo-adjusted effect · Three months after treatment started
Reported findings and study design
Fatigue scores declined in an observational program, with large exclusions from analysis and no untreated group.
2,029 enrolled; 1,170 analyzed; 859 excluded for protocol/documentation problems. Physicians chose two or three months of 100 mg/day treatment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| General-fatigue reduction at three months | 59.1%, 55.9%, 60.5% and 55.7% | Four age-by-duration subgroups; within-person reductions, not a placebo-adjusted effect · Three months after treatment started |
| Post-treatment MFI-20 score | 33.3 points in younger patients; 37.0 in older patients | Ages 45–54 and 55–65; reported overall baseline score 77 · Final follow-up |
| Baseline severity versus subsequent reduction | r=0.789 | Correlational association · p=0.001 |
| Analysis population | 1,170 of 2,029 participants | 859 records excluded; not all enrollment contributed to results |
Reported fatigue reductions by age and treatment duration
| Age / course | General fatigue | Physical fatigue | Reduced activity | Reduced motivation | Mental fatigue |
|---|---|---|---|---|---|
| 45–54 / 2 months | 59.1% | 53.9% | 57.0% | 49.8% | 58.6% |
| 55–65 / 2 months | 55.9% | 48.6% | 53.4% | 47.6% | 55.6% |
| 45–54 / 3 months | 60.5% | 50.7% | 58.9% | 52.2% | 58.6% |
| 55–65 / 3 months | 55.7% | 46.9% | 54.0% | 50.0% | 55.4% |
Reductions from each subgroup baseline at three months after initiation; the two-month groups were assessed one month after stopping. The narrative does not provide subgroup denominators here.
Treatment duration was not randomized and there was no placebo or untreated comparator. The table preserves each subgroup rather than assigning the largest percentage to the whole cohort.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- Large exclusion from analysis creates potential selection bias.
- No untreated control; within-person improvement cannot establish causation.
- This program is not a randomized trial and cannot establish long-term safety.
Source details
Publisher HTML article
Publisher full-text results narrative and available tables checked on 1 November 2026
Sources checked
Citation
A. I. Fedin, E. Yu. Solovyeva, O. P. Mironova, A. V. Fedotova. Treatment of asthenic syndrome in chronic brain ischemia: TRIUMPH observational program Zh Nevrol Psikhiatr Im S S Korsakova. 114(12):104–111
Study source ↗ · DOI 10.17116/jnevro2014114121104-111 · Bibliography entry · Link to this summary